298708-79-9

Usage

Uses

Used in Pharmaceutical Industry:
BAY41-4109 Racemic is used as an antiviral agent for the treatment of Hepatitis B Virus (HBV) infections. It targets the viral replication process by destabilizing the capsid assembly, which is crucial for the virus's ability to replicate and spread within the host.
Additionally, BAY41-4109 Racemic may be used as a research tool in the study of HBV replication mechanisms and the development of novel antiviral therapies. Its potent activity against HBV makes it a valuable compound for understanding the virus's life cycle and identifying potential therapeutic targets.

Upstream product

• 298709-29-2 3,5-difluoropyridine-2-carbonitrile 
• 298709-35-0 methyl 2-(2-chloro-4-fluorobenzylidene)-3-oxobutanoate 
• 298709-32-7 amino(3,5-difluoropyridin-2-yl)methaniminium chloride 

Downstream Products

• 360793-11-9 methyl (R)-6-bromomethyl-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridyl)-1,4-dihydropyrimidine-5-carboxylate 
• 1578153-29-3 (S)-4-[(R)-6-(2-chloro-4-fluoro-phenyl)-2-(3,5-difluoro-pyridin-2-yl)-5-methoxycarbonyl-3,6-dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid 

Relevant academic research and scientific papers

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors

Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors. This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs. X-ray crystallographic study of analogue 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters. The representative analogue 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.

Medicaments against viral diseases

Novel dihydropyrimidines and combinations thereof with other antiviral agents, suitable for combating HBV infections.